- Home
- TGL vs NCNA Comparison
TGL vs NCNA Comparison
Compare TGL & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TGL
- NCNA
- Stock Information
- Founded
- TGL 2020
- NCNA 1997
- Country
- TGL United States
- NCNA United Kingdom
- Employees
- TGL N/A
- NCNA N/A
- Industry
- TGL Retail: Computer Software & Peripheral Equipment
- NCNA Biotechnology: Pharmaceutical Preparations
- Sector
- TGL Technology
- NCNA Health Care
- Exchange
- TGL Nasdaq
- NCNA Nasdaq
- Market Cap
- TGL 3.9M
- NCNA 4.5M
- IPO Year
- TGL 2022
- NCNA 2017
- Fundamental
- Price
- TGL $1.05
- NCNA $0.09
- Analyst Decision
- TGL
- NCNA Buy
- Analyst Count
- TGL 0
- NCNA 2
- Target Price
- TGL N/A
- NCNA $25.00
- AVG Volume (30 Days)
- TGL 2.9M
- NCNA 319.9M
- Earning Date
- TGL 08-25-2025
- NCNA 08-14-2025
- Dividend Yield
- TGL N/A
- NCNA N/A
- EPS Growth
- TGL N/A
- NCNA N/A
- EPS
- TGL N/A
- NCNA N/A
- Revenue
- TGL $1,468,790.00
- NCNA N/A
- Revenue This Year
- TGL N/A
- NCNA N/A
- Revenue Next Year
- TGL N/A
- NCNA N/A
- P/E Ratio
- TGL N/A
- NCNA N/A
- Revenue Growth
- TGL N/A
- NCNA N/A
- 52 Week Low
- TGL $1.01
- NCNA $0.03
- 52 Week High
- TGL $147.00
- NCNA $10.79
- Technical
- Relative Strength Index (RSI)
- TGL 32.05
- NCNA 41.41
- Support Level
- TGL $1.02
- NCNA $0.07
- Resistance Level
- TGL $1.11
- NCNA $0.10
- Average True Range (ATR)
- TGL 0.10
- NCNA 0.03
- MACD
- TGL 0.02
- NCNA 0.01
- Stochastic Oscillator
- TGL 6.44
- NCNA 25.70
About TGL Treasure Global Inc.
Treasure Global Inc has created an online-to-offline e-commerce platform business model offering consumers and merchants instant rebates and affiliate cashback programs, while providing a seamless e-payment solution with rebates in both e-commerce and physical retailers/merchant settings. Its product is an internet application branded ZCITY app, that targets consumers by providing personalized deals based on consumers' purchase history, location and preferences.
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.